Interim report
Page 1
Date: 27th October, 2026 To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra – Kurla Complex Bandra (East) Mumbai – 400 051 Stock Code : INDOCO To The Listing Department Bombay Stock Exchange Limited Floor 25, P. J. Towers, Dalal Street, Mumbai – 400 001 Stock Code : 532612 Dear Sir/Madam, Subject: Outcome of Board Meeting held on 27th October, 2026 Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 27th October, 2026 has inter- alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended 30 th September, 2026 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results. Please find enclosed copies of the following: 1. Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended 30 th September, 2026 as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2. Limited Review Report with unmodified opinion issued by our Statutory A uditors M/s. Gokhale & Sathe, Chartered Accountants. 3. Press Release. The Boa rd Meeting commenced today at 11:2 0 a.m. and concluded at 12:40 p.m. You are requested to kindly take the same on record. Thanking you, Yours faithfully, For Indoco Remedies Limited Ramanathan Hariharan Company Secretary & Head- Legal
Page 2
INDOCO REMEDIES LIMITED e : Indoco House, 166, CST Road, Kalina,Santacr B), Mumbai 400 098. Teli+#91-22-26541851/55 Pax:+91-22-26520787 Email: ८ compliance.officer@indoco.com Website: www.indoco.com CIN:L85190MH1947PLC00591; = STATEMENT OF STANDALONE FINANCIAL RESULTS FOR ‘THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2026 Pst - In Lakhs S.No. Particulars += ended fe = Quarter ended ee Yearended | Half Year ended Year ended | 30,09.2026 30.06.2026 30.09.2025 30.09.2026 30.09.2025 31.03.2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1 | i me from Operations ie | (a) Revenue from Operations 43,806 40,812 42,930 84,618 81,491 1,63,354 | कि) Other Operating Income 1,353 85 1,282 1,438 2,184 5,253 ; 10वें Income from Operations (Net) {atb) 45,159 40,897 44,212 86,056 83,643 1,68,607 2 Other income 502 447 654 949 1,212 2,964 3 Potal Income (1+2) 45,661 41,344 44,806 87,005 84,855 1,71,571 4 penses Lol materials consumed 8,599 8,602 19,602 17,379 oe Ss of stock-in-trade 3,959 3,882 9,539 7,808 14,012 (०) Changes in inventorie: nished goods, 1,487 404 477 (179) 720 work-in-progress and st in-trade if ‘niplayee Bene x 9,456 9,065 9,534 18,521 19,384 39,363 (९) Research & Develapment Expense 2,099 1,854 2,181 3,953 4,347 (1 Othe 25 14,004 11,712 14,270 25,716 28,085 55,520 (13) Vinance Costs 1,987 2,275 2,201 4,262 4,562 8,850 (2) Depreciation and Amortization expense 2,786 2,805 2,763 S591 5,283 10,690 ‘Votal Expenses 45,905 41,756 43,837 87,661 86,666 1,72,432 5 Profit / (Loss) Before Exceptional Items and Tax (3-4) (244) (412) 1,029 (656) (1,811) (861) 6 Exceptional Items [*) 3,714 9,734 (53) 13,448 (53) (286) 7. | Profit Befo x (5+6) 3,470 9,322 976 12,792 (1,864) (1,147) 8 [Tax Expenses - Current 857 1,056 = 1,913 - 292 | - Deferred (450) 34 (529) (416) (563) (873) | - MAT Credit Adjustments : : 2 - - : | Potal Expenses 407 1,090 (529) 1,497 (563) (581) 9. |Profit for the period (7-8) 3,063 8,232 1,505 11,295 (1,301) (566) 10. | Other Comprehensive Income 1 1) hems that will not be reclassified to profit and loss (60) (60) (75) है (150) 178 lis) Incame tax an velating to this item 15 15 19 30 38 (45) b 0 {lems that jay be reclassified to profit or loss - - 152 - 281 [1] Incor x on relating to this item - - (39) - (71) - Total Gther Comprehensive {Income (45) (45) 57 (90) 98 133 11 / Total Comprehensive income for the year (9+10) 3,018 8,187 1,562 11,205 pl (433) 12. {Paid up Fquity Share Capital (Face value Rs. 2/- each) 1,846 1,846 1,845 1,846 1,845 1,846 13 1,08,073 14 | 3.32 8.92 1.63 12.24 (1.41) (0.61) 3132 8.92 1.63 12,23 (1.41) (0.61) he camara i | mudited St idalone Results for the Quarter and Half Year enced 30th September, 2026 have been reviewed by the Audit committee and approved vy the Board of Director = Company at its |inecting beld on 27th October, 2026, The Statutory Auditors have expressed an Unmodified Audit opinion on these unaudited Standalone Financial Results. 2 11161 vs ior corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable, 3 j'The company has only one primary reportable segment of activity, namely, Pharmaceuticals i Net Sales and Income from Operations as per Secondary Segment (Geographica)) is as follows: (Rs. In Lakhs) Net Sales aud Income from Operations ere ended Quarter ended | Quarter ended a ended | Half Year ended Year ended 30.09.2026 30.06.2026 30.09.2025 30.09.2026 30.09.2025 31.03.2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) = 24,304 22,775 24,735 47,079 46,990 89,413 i jWutside India 19,502 18,037 18,195 37539| 34,501 73,941 i 1041 43,806 40,812 42,930) 84,618 81,491) 1,63,354 | | 5 stanutory auditors of the company have carried out limited review of the financial results for the quarter ended 30th September, 2026, pee tional items Curing the quarter includes : on sale of the Company's property situated at Andheri (ast), Mumbai, amounting to Rs 3,663 Lakhs. The property was classified as eld for sale as at 31 March 2026 in accordance with Ind AS 1. deration received Rs. 51 lakhs for grant to use exclusive, perpetual and irrevocable license rights in respect of trademarks of the company, i
Page 3
ent of Assets and Liabilities Bie In Lakhs Larticulars As at 30.09.2026 ie As at 31.03.2026 । बे | 1 (2020 5 | jfa} Property, Plent and Equipment 66,807 3 | 10) Capital Work in Progress 2,394 2,349 । ile 6,373 8,008 | i 328 - | Ife gible Assets under Development 6,966 6,172 111 Right to Use of Asset 10,181 6,791 It 3) Financial Assets ॥ stinents 16,362 15,975 | 8,949 5,056 | Einar ets 1,560 1,633 [1] Deferred ' sets (Net) 289 - (ij Other Non-Current Assets 8,982 8,808 Yolal - Non-Current Assets 1,29,191 1,25,138 2 |Current Assets (६) Inventories 31,339 32,183 (9) Financial Assets (i) investments 1,011 न (it) Trade Receivables 58,070 54,120 [11] Cash and uiva.ents 2,421 1,294 1. Gv) Bank Bala her Than (iii) above 705 706 | [५) Loans 458 456 { {vi} Other Financial Assets 3,619 3,578 I } Current Tax Assets (Net) - 2,136 (d) Other Current Assets 15,726 14,558 (e) Assets Classified as held for Sale 452 2,341 ‘Total - Current Assets 1,13,861 1,11,372 Total - Assets 243,052 2,36,510 Ha] q 1,846 Hb) Our 1,19,130 1,08,073 | Total E 1,20,976 1,09,919 \ ‘Liabilities 2 1) |Non-Current Liabilities () Borrowin, 30,641 (ia) Lease Liabilities 6,505 | [1] Other Financial Liabilities 184 1[0) Provisions 3,323 3,468 iC ) Deferred Tax Lia ilies (Net) : 157 11) Other '४0॥-( nt Liabilities 749 749 विदा - Non-Current Liabilities s 41,402 39,044 b) ilities al Liabilities | ine 40,399 i (ia) Lease Liabilities 1,740 1,156 | (ii) Trade Payables | (A) Total Outstanding Dues of Micro Enterprises 6,822 8,184 | and Smajl Enterprises | (3) Total Outstanding Dues of Other than Micro 15,962 17,871 | Enterp) and Small Enterprises । (il) Other Financial Liabilities 10,001 z | (b) Provisions 4,501 4,041 | (ec) Other Current Liabilities 4,820 5,667 ee iability (net) 719 दे Total - Current Liabilities 80,674 87,547, Liabilities 1,22,076 126,591 Total - Equity and Liabilities | _ | 2,43,052 2,36,510
Page 4
1१५४ tement बा In Lakhs iculars Wy ended 30.09.2026 Period ended 30.09.2025 ‘1 Flow from Operating Activities: ‘et Vrofit/ (Loss) before tax and extraordinary item \cistinents for: Depreciation, Amorti, tien and Impairment Expense 4 cf property, plant and equipment | of property, plant and equipment | | | Gain on sale/dispos: Loss on sale Share § to Employees sundry Balance written baci sion for Doubtful Debts / Bad Debes Intere: Pro Income ‘received on Investments realised Foreign Exchange (Gain) / Loss other than Finance Cost Foreign Exchange (Gain) / Loss in Finance Cost st (Other than Unrealised Foreign Exchange (Gain) / Loss) rating Profit before Working Capital Change justments for: Decrease / (Increase) in Trade Receivables Decrease / (Increase) in Other Current Financial Assets Dee H ase / (Increase) in Other Current Assets | Decrease / (Increase) in Inventories Decrease / (Increase) in Other Non Current Financial Assets Decrease / (Increase) in Other Non 2358 / (Decrease) in Trade Payables in Nan Current Financial Liabilities i / (Decrease) in Non Current Provisions ! 2 / (Decrease) in Lease Liabilities / (Dect ९) in Other Non Current Lia wise / (Decrease) in Current Financial Liabilities se / (Deer in Current Provisions rease / (Decrease) in Other Current Liabilicies es Cash generated from Operations Income Tax Paid (Net of Refund) | Net Cush generated from Operating Activities Before Exceptional dtems...(A)..., | Exceptional items ceptional items cash from/ (used in) Operating Activities (A) low from Investing Activities rchase of property, plant and equipment -ds from sale of property, plant and equipment ston purchases of Investments S ¢)/Decrease in Bank Balance not considered as Cash & Cash Equivalents Interest Received received on Investments vetcash lroni/ (used in) Investing Activities (B) Cash Flow from Financing Activities Finance Cost (Other than Se |} ay Foreign Exchange (Gain) / Loss) Payment of Lease Liabilizy Dividend Paid Proceeds from Long Term Borrowings Repayinent ए Long Term Borrowings Proceeds / (Repayment) from Short Term 801 rowings Net Cash inflow / (outflow) from Financing Activities (९) Net Increase / (Decrease) in Cash or Cash Equivalents (A+B+C) Cash and Cash Equivalents at the beginning of the Period Cash and Cash Equivalents at the end of the Period iy 4,428 (657) 10,468 5,283 (1) 83 (3) 100 (929) (0) (721) 1 3.514 (4,934) (43) (1,166) 844 133 137 (3,246) (1) (265) 3,694 (0) 371 (140) (847) 9,811 5,553) (1,811) 8,409 (12,344) (360) 1,620 945 (531) 7,803 (122) (283) 4,934 8 397 (233 2,527 4,257 942 6,598 | 5,199 13,448 13,448 323 aks ja 7-5) See eS: (5,768) 2,355 (1,398) (3,952) (59) 581 0 (4,424) (839) (186) 5,131 (4,362) __ [4,600 18,647 (8,241) हे 54 265) (169) 929 9 (3,602) (412) (184) (3,047) 1,618 13,072 (4,299) कर 90 706 616 Place : Mumbai Date_: October pee Order of the Board For Indoco Remedigs
Page 8
3) REMEDIES LIMITED Regd. Office : Indoco House, 166, CST Road, Kalina,Santacruz (E), Mumbai 400 098. Teli+91-22-26541851/55 Fax:+91-22-26520787 Email: complianceofficer@indoco,.com Website:www.indoco.com CIN:L85190MH1947PLC005913 STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEP EMBER, 2026 Rs. In Lakhs Partioulars Quarter ended Quarterended | Quarter ended | Half Year ended Half Year ended Year ended 30.09.2026 30.06.2026 30.09.2025 30.09.2026 30.09.2025 31.03.2026 pees as (Unaudited) Unaudited Unaudited Unaudited Unaudited {Audited 1 | dncome from Operations 15] Revenue [rom Operations 50,692 46,622 97,314 90,27 1,79,294 19) Cther Operating Income 1,325 128 1,453 2,165 5,238 total Income from Operations [Net) [atb) 52,017 46,750 98,767 92,435 1,84,532 2 | Other ncome 197 218 416 239 333 3. | ‘Total Income (142) 52,214 | 46,968 99,183 92,674 184,865 4 {Expenses | (aj Cost of materials consumed 12,763 10,458 11,299 23,220 21,851 (h) Purchases of stocs-in-trade 5579 3,989 3,882 9,569 7,805 (c) Changes in inventories of finished goods, (358) 1,358 (047 999 (1,625) wors-in-progress and stock-in-trade 14] Employee Benefits expense 10,511 10,141 23 20,652 21,025 12,569 [९ Research & Deve.cpment Expense 2,098 1854 2,181 3,953 4,347 7,954 (1) Other Expense. 16,781 17,124 31,629 32,973 65,655 (py) Finance Ce 2,691 2,456 5,520 5,068 2,225 11 Depreciation and Amortization expense 3.444 3,225 6,897 6,195 12,645 1019 Expenses 53,509 49,843 2,439 97,639 1,95,222 5 | Profit Before Exceptional Items and Tax (3-4) | (2,295) (1,962) (1,300) 6) (4,965) (10,357) 6 | Exceptional Items (*) 3,714 9,734 : (53) 13,448 (53) (294) 7 | Profit / (Loss) Before Tax (5+6) 2,419 7,772 (1,353) 10,192 (5,018) (10,651) 8 Expenses - Current 861 1,059 5 1920 5 302 (389) 169 (437) (220) (468) (1,083) Expenses 472 1,228 (432) 1,700 (463) (781) 9 [Profit for the period (7-8) 1,947 6,544 (924) 8,492 (4,555) (9,870) 10 | Other Cumprehensive Income a s that will not be reclassified to profit and loss (62) (62) 77) (123) 184 elating, to this item “15 15 19 31 146) b ms that may be reclassified to profit er loss 13 11g 365 131 452 1,262 1] Encome tax on relating to this item न (3) (49) (3) (94) (138) ‘Total Other Comprehensive Income (34) 68 258 36 243 1,262 11 एन Comprehensive income for the year (9+10) 1,913 6,612 (663) 8,528 (4,312) (8,608) Profit attributable to: Equity Sharehulders Company 1,838 6,499 (793) 8,338 (4,371) (9,515) Non-Controlling Interest - Profit / (Loss) 109 45 128) Je as (G4) | Ee ee 59) 1,947 6,544 921 8,492 4,555 (9,870) Other comprehensive income is attributable to: | tquily Sharglolders ef the Company (34) 68 258 36 243 1,262 | Nun-Controlling Interest sa 5 : Z है > 34 68 258 36 243 1,262 | Yotal comprehensive income is attributable to: | | Equity Sharchelders ef the Company 1,804 | 6,567 (535) 8,374 (4,128) sontrolling Interest - Profs / (Loss) | 109 45 128 154 (184 1,913 6,612 663 8,528 4,312 12 | Paid up Equity Share Capital (Face value Rs. 2/- each) 1,846 1,846 1845 1,846 1,845 13. एल Equity 14. |Uarnings per share (of Rs. 2/- each) (a) Basic- in Rs 2.11 (4.94) (10.70) 19) Dihited- ir Rs 241 (4.94) (10.69) ended 30th September, 2026 have been reviewed by the Audit committee ‘Tae company has only one primary reportable segment of activity, namely, Pharmaceuticals. Net Sales and Income trum Operations as per Secondary Segment (Geographical) is as follo cs far corresponding previous periods have been reszated / regrouped wherever necessary, to make them comparable. rofthe Company at its meeting held on 271.1 (1२5. ॥॥ La hs) Net Sales and Income from Operations Quarterended | Quartcrended | Quartcrended | HalfYearended |... Half Ycar ended Year cnded 30.09.2026 30.06.2026 30.09.2025 30.09,2026 30.09.2025 31.03.2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) india 33,577 31177 30,371 64,754 58,153 12612 Outside India 17115 15,445 16,812 32,560 32,117 66,882 Total 50,692 46,622 47,183 97,314 90,270 1,79,294 Consolidated Financial Re neludes the Results of t 2 following Companies Name Se SL ie oe eee eens ewe the Company हि of Shareholding | Consolidated as Ntend Industrial Designers & Engineers Pvt, Ltd. 100 |= lidocu Remedies Czech $ RO 100 Subsidiary 11000 Remedies UK Ltd. 100 Subsidiary Warren Remedies Private Limited 190 Subsidiary Warren Lifesciences Private Limited | 100 Subsidiary PRD old neseier many We Wise wee Nek Ne ey ice le 8S Subsidiary 6 |The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 30th September, 2026. 17] Exceptional items curing the quarter includes (8) Gain on 58.0 of the Company's property situated at Andheri (East), Mumbai, amounting to Rs 3,663 Lakhs, The property was classified as held fer sale as at 31 March 2026 in accordance with Ind AS 105, (b) Consideration received Rs. 51 lakhs for grant to use exclusive, perpetual and irrevocable license rights in respect of trademarks of the company, 8 Warren Lifesciences Private Limited was incorporated on 26 September 2026 and is considered a wholly-owned subsidiary of Indoce Remedies Limited in accordance with Ind AS 110.
Page 9
9 Statement of Assets and Liabilities 1 In Lakhs | Sr. Particulars As at 30.09.2026 AS at 31.03.2026 ee = —— A |ASSETS 1 wrent Assets [a] Property, Plant and Equipment 92,940 96,983 कि) Capital Work in Progress 2,077 2,829 fe] Goedwill er Consolidation 2,152 2,152 11,769 | ets under Development 6,172 | (a) Right to Use of Asset 8,407 (hi) Financial Assets (i) Investinents 146 (ii) Loans 327 (iii) Othe: Financial Assets 2,251 (i) Other Non-C 11 Assets 8,956 ‘Total -Non-Current Assets L । Current Assets [a] lnventories 39,665 10,521 | [01 Finane:al Assets (i) Investments 1,011 (ii) Trade Receivabies 53,755 18,917 | (ii) Cash and Cash Equivalents 3,477 2,593 | fiv] Bank Balances Other Than (i1i) above 765 706 (५) Loans +468 465 (vi) Other Financial Assets O46 597 (c) Current Tax Assets (Net) a 2,156 (1 Other ent Assets 22,325 [2] Assets Classified as held for Sale 452 ‘Total - Current Assets 1,22,563 । _ [19191 - Assets 2,61,274 2,59,327 B [Equity and Liabilities 1. {Equity (a) Guilty Share Capital 1,846 1,846 (b) Other Equity 1,00,308 92,082 (थे Non-Ce ng Interest 562 TAT Total, Equity attributable to equity holders of the Company 1,01,592 98,211 2. |Liabilities a) Current Liabilities (a) Financial Liabilities 11] Borrowings 51,375 \ (ia) Lease Liabilities 5,534 | 81 Other Financial Liabilities 184 | ‘(Hp Provisions 3,423 | 1०) Deferred Pas Liabiliti 189 249 otal Non-Current Liabilities 62,453 hb) |Current Liabilities (a) Financial Liabili ()) Borrowings 46,235 5 983 (ia} Lease Liabilities 1,775 1,15¢ (i) Trade Payables (Aj Total Outstanding Dues ef Micro Enterprises 8,825 9,026 and Small Enterprises (B) Total Outstanding Dues ef Other than Micre 19,084 Enterprises aad Small Esterprises ) Other Financial Liabilities 11,164 10,745 (hb) @rovisions 4,535 4,086 (¢} Income Tax Liabilities (Net) 695 rs (dj Other Current Liabilities 4,917 5,827 Votal - Current Liabilities 97,229 105,254 | Total Liabilities 159,681 166,116 otal - Equity and Liabilities 2,61,274 259/327)
Page 10
ish Flow Statement 7 ata: In Laldisy | Particulars Period ended 30,09.2026 Period ended 30.09.2025 | cash Flow trom Operating Acti | Net Profit / (Loss) before tax aud extraordinary item 3,255) । )॥|ए्ालाछ for : | Depreciation, Amortisation and linpairment Expense 6,897 | Gain on sale/disposal of property, tand equipment (5) Loss on sale/disposal of property, plant and equipment 21 Share based payments to Employees 37 Sundry Balance written back G) Provision for Doubtful Debts / Bad Debts 311 Interest Income (222) Vividend received on Investments: (9) ' Unrealised Forel 2 (G 55, Unreal a 0 (417) | Fivance Cos: (Uther thas Unrealised Foreign Exchange (Gain) / Loss) 937 13,109 = _ 10,719 | 9,854 S783 | Operating Profit before Working Capital Change | Adjustments for: | Decrease / (Increase) in Trade Receivables (5,537) | D se / (Increase) in Other Current Financial Assets (51) Decrease / (Increase) in Other Current Assets (1,286) Decrease / (Increase) in Inventories 856 Decrease / (Increase) in Other Non Current Financial Assets 147 | Decrease / (Increase) in Other Non Current Assets 142 | Increase / (Decrease) in Trade Payables (2,825) | crease / (Decrease) in Nen Current Financial Liabilities (91) Increase / (Decrease) in Nen Current Provisions (265) Increase / (Decrease) in Lease Liabilities 3,758 | Inervase / (Decrease) in Other Non Current Liabilicies (0) | ० / (Decrease) in Cu icial Liabilities 441 | | Increase / (Decrease) in Current Provisions (153) Increase / (Decrease) in Other Current Liabilities (911 See te 5,776 | Cash generated from Operations 4,078 130 Income Tax Paid (Net of Refund) 981 (348) Net Cash generated from Operating Activities Before Exceptional Items....(A).... 5,008 14,782 Exceptional Items Exception 13,448 हे | Net Cash generated from Operating Activities (A) 18,456 (8) | Cash Flow from Investing Activities Purchase of property, plant and equipment (6,049) (10,374) Proceeds from sale of property, plant and equipment 2,361 4,528 Payment on purchases of Investments (1,398) : (Increase) /Decrease in Bank Balance not considered as Cash & Cash Equivalents (59) (169) Interast Received 222 59 Dividend received on Investments 2 = Net Cash used in Investing Activities (8) (4,923) (5,956) (0) | Cash Flow from Financing Activities # nance Cost (Other than Unrealized Poreign Exchange (Gain) / L (5,900) (4,117) ayment of Lease Liability (839) (412) vidend Paid (186) (184) 7,467 8 (6,897) Proceeds / (Repayment) (६ rowings mo (6.194) | inflow / (outflow) from Financing Activities (C) | 12,649] हे | ase / (Decrease) in Cash or Cash Equivalents (A+B+C) 88 sh and Cash Equivalents at the beginning of the Period | 2,593, hand Cash Equivalents atthe endofthePeriod | 3,477 i 1,266 By Order of the Board For Indoco Remedies Ltd Place: Mumbai hice ८7 Midilar [ Date : October 27, 2026 ng Director
Page 14
PRESS RELEASE Indoco Q2 consolidated revenues grow 7.4 % YoY Mumbai, October 27, 2026: During the second quarter of FY 2026-27, consolidated revenues of Indoco Remedies are at ₹ 5,069 mn, as against ₹ 4,718 mn for the same quarter last year, thus recording growth of 7.4% YoY. EBIDTA to net sales for the quarter is 9.2 % at ₹ 464 mn, compared to 9.1 % at ₹ 431 mn for the same quarter last year. For the first half of FY 2026-27, consolidated revenues of Indoco Remedies are at ₹ 9,731 mn, as against ₹ 9,027 mn for the same period last year, with a growth of 7.8%. EBIDTA to net sales for the period is 9% at ₹ 875 mn, compared to 6.7% at ₹ 606 mn for the same period last year. Commenting on the results, Ms. Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, “The second quarter of the financial year 2026 -27 reflects o ur continued focus on improved b usiness performance along with strengthening our operational efficiency. Our regulated international formulations business delivered strong performance (+21.1% growth in Q2FY27), while our API (+22.0% in H1) and Allied Services (+27.4 % in H1) continued their strong momentum. As Indoco enters its next phase under the New Indoco – 80 Years Forward, we remain committed to building a resilient, competitive and diversified pharmaceutical business that delivers sustainable long -term growth and creates enduring value for our stakeholders. About Indoco Remedies Limited: Indoco is a fully integrated, research -oriented pharmaceutical company with a strong global presence. The Company’s turnover is US$ 1 75 million with human capital of over 6000 employees, including over 300 skilled scientists and field staff who are the strength of the organization. The Company has 1 0 manufacturing facilities, 6 for FDFs and 4 for APIs, supported by a state -of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK -MHRA. Indoco develops and manufactures a wide range of pharmaceutical pr oducts for the Indian and international markets. It generates more than 10 5 million prescriptions annually from over 2, 39,000 doctors belonging to various specialties. Indoco has 8 domestic marketing divisions, a strong brand portfolio in various therapeutic segments including Gastro -intestinal, Respiratory, Anti -Infectives, Stomatologicals, Nutritionals, Cardiovascular, Anti -Diabetics, Pain Management, Gynaecology, etc. Top Indoco brands include Cyclopam, Febrex Plus, ATM, Rexidin M, Karvol Plus, Oxipod, Cital, Sensodent-K, Cital-Uti, Dropizin, Dentogel,
Page 15
Oxipod CV, Turbocort, Febrex, Cloben G, Tuspel LS, Noxa, MCBM 69, etc. On the international front, Indoco has tie-ups with large generic companies across the globe. For more details on Indoco, you may visit www.indoco.com For investor relations queries please contact: Contact- +91 22 68321400 Email: Ninad.Paradkar@indoco.com / corpcom@indoco.com